• Seres Therapeutics posted a net loss of USD 19.9 million, or USD 2.08 per share, swinging from net income of USD 32.7 million a year earlier.
• Revenue totaled USD 358,000, while operating loss narrowed to USD 20.9 million as operating expenses fell to USD 21.3 million.
• Cash and cash equivalents declined to USD 29.8 million, with runway expected to extend through the third quarter of 2026.
• Enrollment completed in an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis, with clinical data expected in coming weeks.
• SER-155 remained Phase 2 ready in allo-HSCT pending funding, while IND-enabling work continued for SER-603 in inflammatory bowel disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050700PRIMZONEFULLFEED9712958) on May 05, 2026, and is solely responsible for the information contained therein.